ABSTRACT #24-11187

N-803 plus BCG Complete Response rate in NMIBC CIS subjects: BCG refractory, relapsed, checkpoint failure, and chemotherapy failure; updated results (QUILT 3.032)

BACKGROUND

Patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive NMIBC have limited treatment options and are at an increased risk for cystectomy. N-803 (nogapendekin alfa inbakicept: ANKTIVA®), is an interleukin-15 superagonist (IL-15) [1], which synergizes with BCG to elicit durable complete responses (CRs) and is FDA approved for BCG-unresponsive NMIBC CIS with or without papillary tumors [2].

The open-label, 3-cohort, multicenter phase 2/3 study QUILT 3032 (NCT03022825), November 30, 2023 data cutoff, interim data is presented with responses ongoing, including sub-analyses based on disease type and treatment history.

METHODS

Preparation of BCG and ANKTIVA Admixture

For Intravesical Use Only. Do NOT administer by subcutaneous or intravenous or intramuscular routes.



BCG Diluted in 50 mL Saline

Prepare BCG suspension following the instructions provided in the Prescribing Information for BCG with saline as follows:

Draw 1 mL of sterile, preservative-free saline (0.9% Sodium Chloride Injection USP) from a 50 mL vial of sterile saline at 4-25°C into a small syringe (e.g., 3 mL) and add to 1 vial of BCG to resuspend. Ensure that the needle is inserted through the center of the rubber stopper of the vial. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria.

Dilute the cloudy BCG suspension in the same 50 mL sterile preservative-free saline vial to a final volume of 50 mL. Mix the suspension gently prior to step 2.

Step 2



Anktiva Admixed in 50 mL Saline with BCG

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution is clear to slightly opalescent and colorless to slightly yellow. Discard the vial if visible particles are observed. Draw 0.4 mL of **ANKTIVA** into a small syringe and using aseptic technique add to the 50 mL saline volume containing the BCG suspension from step 1 that has been prepared following the instructions provided in the Prescribing Information for BCG.

Mix the suspension gently.

50 mL Admixed Volume Transferred to 60 mL Syringe





Step 3


Using a **60-mL syringe** connected to an appropriate size needle, withdraw the ANKTIVA BCG mixture to a final volume of 50 mL


If the admixture of ANKTIVA in combination with BCG is not used immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) and use within 2 hours. Unused solution of admixture should be discarded after 2 hours.


METHODS











Patrick Soon-Shiong^e, Karim Chamie^a, Sam S. Chang^b, Eugene V. Kramolowsky^c, Mark L. Gonzalgo^d, Sandeep K. Reddy^e

